Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor


Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products

Originally posted here:
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Related Posts